Vertex Pharmaceuticals announced that the European Medicines Agency’s, or EMA, Committee for Medicinal Products for Human Use, or CHMP, adopted am opinion for the label extension of Kaftrio in a combination regimen with ivacaftor, for the treatment of children with cystic fibrosis, or CF, ages two through five years old who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on VRTX:
- Vertex appoints Atkinson EVP Chief Technical Operations Officer
- Vertex Pharmaceuticals price target raised to $315 from $312 at Canaccord
- Vertex: VX-548 preclinical studies, Phase 2, proof-of-concept results published
- Vertex Pharmaceuticals price target raised to $425 from $410 at Wells Fargo
- Vertex Pharmaceuticals price target raised to $370 from $360 at TD Cowen